2014
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA. Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research 2014, 20: 1757-1767. PMID: 24398047, PMCID: PMC3998833, DOI: 10.1158/1078-0432.ccr-13-2332.Peer-Reviewed Original ResearchConceptsEstrogen receptor α mutationBreast cancerAdvanced estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerHormone-dependent breast cancerPrimary breast cancerSubgroup of patientsER-negative tumorsLine of treatmentCodon 537ER- diseaseEndocrine treatmentTreatment-naïveESR1 mutationsMetastatic diseaseCell line modelsEndocrine resistanceMetastatic tumorsReceptor constitutive activityEstrogen receptorMetastatic samplesTumor specimensCancer-related genesNatural history
2013
DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes
Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, André F, Turner NC, Symmans WF, Hortobágyi GN, Pusztai L, Bianchini G. DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. The Oncologist 2013, 18: 1063-1073. PMID: 24072219, PMCID: PMC3805146, DOI: 10.1634/theoncologist.2013-0163.Peer-Reviewed Original ResearchConceptsResidual invasive cancerHER2-negative tumorsInvasive cancerER-positive/HER2-negative tumorsPredictive valueUntreated breast cancer patientsAffymetrix gene expression profilesHER2-negative subgroupMolecular breast cancer subtypesTaxane/anthracyclinePathological complete responseER-positive tumorsAnthracycline-treated patientsHER2-positive tumorsBreast cancer patientsER-negative tumorsBreast cancer subtypesAnthracycline regimensComplete responseBetter prognosisClinical outcomesBC patientsPoor prognosisPredictive factorsPrognostic value
2012
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer
McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Research 2012, 14: r72. PMID: 22559056, PMCID: PMC3446334, DOI: 10.1186/bcr3181.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalAutoantigensBiomarkers, TumorBreast NeoplasmsCentromere Protein ACentromere Protein BChromosomal Proteins, Non-HistoneDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansKi-67 AntigenMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalReceptors, EstrogenRNA, MessengerTamoxifenConceptsER-positive diseaseDistant relapse-free survivalSystemic therapyER-negative tumorsIndependent prognostic markerNeoadjuvant chemotherapyPrognostic markerBreast cancerChemotherapy responseKi-67Estrogen receptor-positive breast cancerReceptor-positive breast cancerER-positive breast cancerSignificant independent prognostic markerER-positive tumorsRelapse-free survivalBreast cancer patientsHigh-grade cancerSignificant independent predictorsKi-67 expressionFree survivalHazard ratioIndependent predictorsPrognostic factorsNegative tumors
2009
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research 2009, 11: r15. PMID: 19272155, PMCID: PMC2688939, DOI: 10.1186/bcr2234.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunoenzyme TechniquesLymphocyte Specific Protein Tyrosine Kinase p56(lck)Neoplasm StagingOligonucleotide Array Sequence AnalysisPrognosisReceptor, ErbB-2Receptors, EstrogenT-LymphocytesConceptsER-negative tumorsImmune cellsBreast cancer samplesSurrogate markerPrognostic valueBreast cancerHuman epidermal growth factor receptor 2 (HER2) amplificationHER2-positive breast cancerDifferent immune cell typesCancer samplesPrimary breast cancer samplesER-negative groupER-positive tumorsDifferent immune cellsSignificant prognostic valuePositive prognostic valueImmune cell typesSubgroup of tumorsPrognostic gene signatureNeoadjuvant chemotherapyFavorable prognosisCytokine milieuClinical parametersNegative tumorsWorse prognosis
2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
Mazouni C, Kau S, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals Of Oncology 2007, 18: 874-880. PMID: 17293601, DOI: 10.1093/annonc/mdm008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged-Ring CompoundsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMiddle AgedNeoplasms, Hormone-DependentPaclitaxelPrognosisReceptors, EstrogenSurvival AnalysisTaxoidsTumor BurdenConceptsPathologic complete response rateComplete response rateER-negative tumorsPreoperative chemotherapyPCR rateER statusBreast cancerResponse rateEstrogen receptor-positive breast cancerReceptor-positive breast cancerMD Anderson Cancer CenterBreast cancer benefitER-negative statusInclusion of taxanesER-negative patientsER-positive patientsER-positive tumorsNeo-adjuvant therapyType of regimenClinical tumor sizeSubset of patientsCox regression analysisER-negative cancersPositive breast cancerAnderson Cancer Center